Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | TSHR | P16473 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13085712 | 0.96 | ALDH1A1 (0.47) | ALDH1A1TSHRMAPTHIF1AHPGD | |
| SCHEMBL14601522 | 0.96 | ALDH1A1 (0.47) | ALDH1A1TSHRMAPTHIF1AHPGD | |
| SCHEMBL677953 | 0.96 | ALDH1A1 (0.47) | ALDH1A1TSHRMAPTHIF1AHPGD | |
| SCHEMBL13003246 | 0.95 | ALDH1A1 (0.46) | ALDH1A1TSHRMAPTHIF1AHPGD | |
| SCHEMBL15788352 | 0.95 | ALDH1A1 (0.46) | ALDH1A1TSHRMAPTHIF1AHPGD | |
| SCHEMBL676687 | 0.94 | ALDH1A1 (0.47) | ALDH1A1TSHRMAPTHIF1AHPGD | |
| SCHEMBL14601521 | 0.93 | ALDH1A1 (0.44) | ALDH1A1TSHRMAPTHIF1AHPGD | |
| SCHEMBL13238280 | 0.91 | KMT2A (0.52) | ALDH1A1TSHRMAPTHIF1AHPGD | |
| SCHEMBL16727407 | 0.90 | ALDH1A1 (0.42) | ALDH1A1TSHRMAPTHIF1AHPGD | |
| SCHEMBL16727408 | 0.90 | ALDH1A1 (0.42) | ALDH1A1TSHRMAPTHIF1AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275170-A1 | METAL OXIDE NANOPARTICLES, METHODS OF MAKING, AND METHODS OF USE | CITIBANK, N.A., AS COLLATERAL AGENT | 2008-11-06 | — | — | US | claimed |
| EP-1954732-A1 | COMPOSITIONS FOR BRIGHTNESS ENHANCING FILMS | General Electric Company (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007001811-A1 | COMPOSITIONS FOR BRIGHTNESS ENHANCING FILMS | GENERAL ELECTRIC COMPANY (US) | 2007-01-04 | — | — | WO | claimed |
| US-20060293463-A1 | Compositions for brightness enhancing films | GENERAL ELECTRIC COMPANY | 2006-12-28 | — | — | US | claimed |
| EP-1631603-B1 | CURABLE (METH)ACRYLATE COMPOSITIONS | GEN ELECTRIC (US) | 2006-11-22 | — | — | EP | claimed |
| US-7087659-B2 | Curable (meth)acrylate compositions | GENERAL ELECTRICAL (US) | 2006-08-08 | — | — | US | claimed |
| US-6833391-B1 | Comprising three monomers having highly brominated phenyl, arylether and bisphenol A or F functionality and initiator; light management films; high refractive index; brightness | GENERAL ELECTRIC COMPANY | 2004-12-21 | — | — | US | claimed |
| US-20040249100-A1 | CURABLE (METH)ACRYLATE COMPOSITIONS | GENERAL ELECTRIC COMPANY (US) | 2004-12-09 | — | — | US | claimed |
| US-20040242720-A1 | Curable (meth)acrylate compositions | CITIBANK, N.A., AS COLLATERAL AGENT | 2004-12-02 | — | — | US | claimed |
| US-20230323087-A1 | Antimony Trioxide Free Flame Retardant Polymer Composition | LANXESS CORPORATION (US) | 2023-10-12 | — | — | US | disclosed |
| US-9631144-B2 | Flame retardant composition | BROMINE COMPOUNDS LTD. (IL) | 2017-04-25 | — | — | US | disclosed |
| US-9631144-B2 | Flame retardant composition | BROMINE COMPOUNDS LTD. (IL) | 2017-04-25 | — | — | US | disclosed |
| US-9315731-B2 | High impact polystyrene flame retarded compositions | BROMINE COMPOUNDS LTD. (IL) | 2016-04-19 | — | — | US | disclosed |
| US-9315731-B2 | High impact polystyrene flame retarded compositions | BROMINE COMPOUNDS LTD. (IL) | 2016-04-19 | — | — | US | disclosed |
| US-20050049376-A1 | High refractive index, uv-curable monomers and coating compositions prepared therefrom | GENERAL ELECTRIC COMPANY | 2005-03-03 | — | — | US | disclosed |
| EP-1510557-A2 | Metal oxide nanoparticles | GENERAL ELECTRIC COMPANY (US) | 2005-03-02 | — | — | EP | disclosed |
| US-6833391-B1 | Comprising three monomers having highly brominated phenyl, arylether and bisphenol A or F functionality and initiator; light management films; high refractive index; brightness | GENERAL ELECTRIC COMPANY | 2004-12-21 | — | — | US | disclosed |
| WO-2004106396-A1 | CURABLE (METH)ACRYLATE COMPOSITIONS | GENERAL ELECTRIC COMPANY (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040249100-A1 | CURABLE (METH)ACRYLATE COMPOSITIONS | GENERAL ELECTRIC COMPANY (US) | 2004-12-09 | — | — | US | disclosed |
| US-20040242720-A1 | Curable (meth)acrylate compositions | CITIBANK, N.A., AS COLLATERAL AGENT | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049376-A1 | High refractive index, uv-curable monomers and coating compositions prepared therefrom | MACF1, WASF2, THEM6 | ALDH1A1 1014/4885TSHR 4739/4885MAPT 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.